Taxanes chemotherapeutic regiments-induced peripheral neurotoxicity
Conditions
Interventions
Cohort 1 (Patients who have been pathologically diagnosed with a malignant solid tumor and plan to receive taxane chemotherapy):None
Cohort 2 (Patients who develop chemotherapy-induced peripheral neuropathy (CIPN) caused by taxane chemotherapeutic drugs ):None
Sponsors
The First Affiliated hospital of Jinzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Confirmed diagnosis of malignant solid tumor by pathological or cytological examination. 2.Aged >= 18 years, with no restriction on gender. 3.Clear consciousness and ability to independently complete all questionnaires. 4.Receiving taxane-based chemotherapy for = 2 cycles.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of grade II or higher chemotherapy-induced peripheral neuropathy (CIPN). 2.Patients with nerve compression symptoms caused by brain metastasis or metastasis to other sites. 3.Patients with neurological disorders caused by non-chemotherapeutic factors, such as electrolyte imbalance or other systemic diseases (e.g., severe cervical spondylosis, intervertebral disc compression, diabetes mellitus). 4.Patients with hand-foot skin lesions. 5.Patients with contraindications to taxane drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whether peripheral neurotoxicity occurs (Yes or No);Severity of Peripheral Neurotoxicity; | — |
Countries
China
Contacts
Public ContactZhenhua Zhai
The First Affiliated hospital of Jinzhou Medical University
Outcome results
None listed